source
- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury, k…Endpoints · 13d ago↗ source
- Nava Therapeutics emerges with $89M for lipid nanoparticlesNava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney, has raised $89 million, the company t…Endpoints · 15d ago↗ source
- Otsuka reports long-term kidney data key to Voyxact's bid for full approvalOtsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabiliz…